These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30532240)

  • 21. Model-Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives.
    Marshall S; Madabushi R; Manolis E; Krudys K; Staab A; Dykstra K; Visser SAG
    CPT Pharmacometrics Syst Pharmacol; 2019 Feb; 8(2):87-96. PubMed ID: 30411538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.
    Croteau D; Pinnow E; Wu E; Muñoz M; Bulatao I; Dal Pan G
    Drug Saf; 2022 Feb; 45(2):169-180. PubMed ID: 35113347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing drug safety of hepatitis C therapies using post-market data.
    Huang J; Zhang X; Tong J; Du J; Duan R; Yang L; Moore JH; Tao C; Chen Y
    BMC Med Inform Decis Mak; 2019 Aug; 19(Suppl 4):147. PubMed ID: 31391106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System.
    Iyer G; Marimuthu SP; Segal JB; Singh S
    Drug Saf; 2017 Sep; 40(9):799-808. PubMed ID: 28593504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Teaching an old drug new tricks: Regulatory insights for the repurposing of hemin in cardiovascular disease.
    Eadie AL; Simpson JA; Brunt KR
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1225. PubMed ID: 38923404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Web-based drug repurposing tools: a survey.
    Sam E; Athri P
    Brief Bioinform; 2019 Jan; 20(1):299-316. PubMed ID: 29028878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse effects in women: implications for drug development and regulatory policies.
    Parekh A; Fadiran EO; Uhl K; Throckmorton DC
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):453-66. PubMed ID: 22114855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions.
    Sekine S; Pinnow EE; Wu E; Kurtzig R; Hall M; Dal Pan GJ
    Clin Pharmacol Ther; 2016 Jul; 100(1):102-8. PubMed ID: 26853718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining automatic table classification and relationship extraction in extracting anticancer drug-side effect pairs from full-text articles.
    Xu R; Wang Q
    J Biomed Inform; 2015 Feb; 53():128-35. PubMed ID: 25445920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and regulatory features of drugs not initially approved by the FDA.
    Wang B; Avorn J; Kesselheim AS
    Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PISTON: Predicting drug indications and side effects using topic modeling and natural language processing.
    Jang G; Lee T; Hwang S; Park C; Ahn J; Seo S; Hwang Y; Yoon Y
    J Biomed Inform; 2018 Nov; 87():96-107. PubMed ID: 30268842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Expanded Access on FDA Regulatory Action and Product Labeling.
    Jarow JP; Moscicki R
    Ther Innov Regul Sci; 2017 Nov; 51(6):787-789. PubMed ID: 30079277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ophthalmic Drug Discovery and Development: Regulatory Aspects of Patient Focused Drug Development in Ophthalmology.
    Rowe-Rendleman CL
    Pharm Res; 2019 Feb; 36(4):54. PubMed ID: 30790065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse Drug Reaction Risk Measures: A Comparison of Estimates from Drug Surveillance and Randomised Trials.
    Beau-Lejdstrom R; Crook S; Spanu A; Yu T; Puhan MA
    Pharmaceut Med; 2019 Aug; 33(4):331-339. PubMed ID: 31933187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Open-source chemogenomic data-driven algorithms for predicting drug-target interactions.
    Hao M; Bryant SH; Wang Y
    Brief Bioinform; 2019 Jul; 20(4):1465-1474. PubMed ID: 29420684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
    Szarfman A; Machado SG; O'Neill RT
    Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors Influencing Regulatory Decision-Making in Signal Management: Analysis Based on the Signals Identified from the FAERS.
    Fukazawa C; Hinomura Y; Kaneko M; Narukawa M
    Ther Innov Regul Sci; 2021 Jul; 55(4):685-695. PubMed ID: 33721283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
    Downing NS; Shah ND; Aminawung JA; Pease AM; Zeitoun JD; Krumholz HM; Ross JS
    JAMA; 2017 May; 317(18):1854-1863. PubMed ID: 28492899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overcoming Sparseness of Biomedical Networks to Identify Drug Repositioning Candidates.
    Poleksic A
    IEEE/ACM Trans Comput Biol Bioinform; 2022; 19(4):2377-2384. PubMed ID: 33591920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.